Cassava Sciences Ownership
| SAVA Stock | USD 26.48 5.70 17.71% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 46.2 M | Current Value 48 M | Avarage Shares Outstanding 12.6 M | Quarterly Volatility 13.3 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Cassava |
Cassava Stock Ownership Analysis
About 13.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.38. Cassava Sciences last dividend was issued on the 13th of December 2012. The entity had 1:7 split on the 10th of May 2017. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Cassava Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. To find out more about Cassava Sciences contact Remi Barbier at 512 501 2444 or learn more at https://www.cassavasciences.com.Besides selling stocks to institutional investors, Cassava Sciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cassava Sciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cassava Sciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cassava Sciences Quarterly Liabilities And Stockholders Equity |
|
Cassava Sciences Insider Trades History
About 13.0% of Cassava Sciences are currently held by insiders. Unlike Cassava Sciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cassava Sciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cassava Sciences' insider trades
Cassava Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cassava Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cassava Sciences backward and forwards among themselves. Cassava Sciences' institutional investor refers to the entity that pools money to purchase Cassava Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Clear Creek Investment Mgmt Llc | 2024-09-30 | 153.5 K | Norges Bank | 2024-06-30 | 147.6 K | Bank Of New York Mellon Corp | 2024-06-30 | 140.8 K | Bank Of America Corp | 2024-06-30 | 120.6 K | Jane Street Group Llc | 2024-06-30 | 120.1 K | Susquehanna Portfolio Strategies Llc | 2024-06-30 | 105.4 K | Swiss National Bank | 2024-09-30 | 89 K | Advisor Group Holdings, Inc. | 2024-06-30 | 86.4 K | Goldman Sachs Group Inc | 2024-06-30 | 85.2 K | Blackrock Inc | 2024-06-30 | 3.2 M | Vanguard Group Inc | 2024-09-30 | 2.5 M |
Cassava Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cassava Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cassava Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cassava Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cassava Sciences Outstanding Bonds
Cassava Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cassava Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cassava bonds can be classified according to their maturity, which is the date when Cassava Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Cassava Sciences Corporate Filings
F3 | 20th of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 1st of October 2024 An amendment to a previously filed Form 8-K | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cassava Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cassava Sciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cassava Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cassava Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cassava Sciences. If investors know Cassava will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cassava Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.38) | Return On Assets (0.46) | Return On Equity (0.11) |
The market value of Cassava Sciences is measured differently than its book value, which is the value of Cassava that is recorded on the company's balance sheet. Investors also form their own opinion of Cassava Sciences' value that differs from its market value or its book value, called intrinsic value, which is Cassava Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cassava Sciences' market value can be influenced by many factors that don't directly affect Cassava Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cassava Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cassava Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cassava Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.